Compare SYNX & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYNX | CELZ |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | Israel | United States |
| Employees | 37 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.8M |
| IPO Year | 2023 | 2008 |
| Metric | SYNX | CELZ |
|---|---|---|
| Price | $1.07 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.4K | ★ 8.1M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,000.00 |
| Revenue This Year | $32.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $0.79 |
| 52 Week High | $2.15 | $6.25 |
| Indicator | SYNX | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 28.72 |
| Support Level | $1.04 | $0.79 |
| Resistance Level | $1.25 | $2.33 |
| Average True Range (ATR) | 0.07 | 0.43 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 34.44 | 2.82 |
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sells push-to-talk devices, communication controllers, and communication device cables and connectors. Geographically, it generates the majority of its revenue from Israel.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.